2021-2027 Global and Regional Alpha 1 Antitrypsin Deficiency Treatment Industry Status and Prospects Professional Market Research Report Standard Version
Date: Aug-2021 | Id: MACRC-72402 | Geographical Scope: Global | Publisher: Mnemonics Research
The global Alpha 1 Antitrypsin Deficiency Treatment market was valued at 113.05 Million USD in 2020 and will grow with a CAGR of 10.09% from 2020 to 2027, based on Mnemonics Research newly published report. The prime objective of this report is to provide the insights on the post COVID-19 impact which will help market players in this field evaluate their business approaches. Also, this report covers market segmentation by major market verdors, types, applications/end users and geography(North America, East Asia, Europe, South Asia, Southeast Asia, Middle East, Africa, Oceania, South America). Severe deficiency of alpha-1 antitrypsin (AAT) can cause early-onset emphysema and several liver diseases, including cirrhosis, neonatal hepatitis and hepatocellular carcinoma.The discovery of the structure and function of the AAT protein and the subsequent isolation and purification thereof have made possible alternative therapies aimed at preventing the progression of related pulmonary diseases (so-called "additional therapies"). The isolation of this gene and the advancement of gene therapy have further increased the possibility of specific treatment. Most specific treatments for AAT deficiency aim to increase plasma AAT levels (and thus elevated AAT concentrations in the interstitial lung) above the protection threshold. Other experimental therapeutic approaches attempt to interfere with the production of abnormal AAT proteins or to inhibit the polymerization of abnormal AAT proteins and to promote the secretion of AAT from hepatocytes. For patients with end-stage lung disease or liver disease, organ transplantation is another treatment option. Currently, the most direct and effective way to increase AAT levels in plasma and interstitial lung is by intravenous infusion of pooled alpha-1 antitrypsin (pAAT). By Market Verdors: Pfizer Baxter AstraZeneca Grifols Teva Pharmaceutical Industries Boehringer Ingelheim Kamada Ltd GlaxoSmithKline CSL Behring Shire LFB Biomedicaments Abeona Therapeutics Biogen Applied Genetic Technologies Baxalta Arrowhead Research Corporation ProBioGen Chiesi Pharmaceuticals Curaxys ProMetic Life Sciences By Types: Augmentation Therapy Bronchodilators Corticosteroids Oxygen Therapy By Applications: Hospitals Specialty Clinics Pharmacies Key Indicators Analysed Market Players & Competitor Analysis: The report covers the key players of the industry including Company Profile, Product Specifications, Production Capacity/Sales, Revenue, Price and Gross Margin 2016-2027 & Sales with a thorough analysis of the market’s competitive landscape and detailed information on vendors and comprehensive details of factors that will challenge the growth of major market vendors. Global and Regional Market Analysis: The report includes Global & Regional market status and outlook 2016-2027. Further the report provides break down details about each region & countries covered in the report. Identifying its sales, sales volume & revenue forecast. With detailed analysis by types and applications. Market Trends: Market key trends which include Increased Competition and Continuous Innovations. Opportunities and <b>Drivers:</b> Identifying the Growing Demands and New Technology Porters Five Force Analysis: The report provides with the state of competition in industry depending on five basic forces: threat of new entrants, bargaining power of suppliers, bargaining power of buyers, threat of substitute products or services, and existing industry rivalry. Key Reasons to Purchase To gain insightful analyses of the market and have comprehensive understanding of the global market and its commercial landscape. Assess the production processes, major issues, and solutions to mitigate the development risk. To understand the most affecting driving and restraining forces in the market and its impact in the global market. Learn about the market strategies that are being adopted by leading respective organizations. To understand the future outlook and prospects for the market. Besides the standard structure reports, we also provide custom research according to specific requirements.
Chapter 1 Industry Overview 1.1 Definition 1.2 Assumptions 1.3 Research Scope 1.4 Market Analysis by Regions 1.4.1 North America Market States and Outlook (2022-2027) 1.4.2 East Asia Market States and Outlook (2022-2027) 1.4.3 Europe Market States and Outlook (2022-2027) 1.4.4 South Asia Market States and Outlook (2022-2027) 1.4.5 Southeast Asia Market States and Outlook (2022-2027) 1.4.6 Middle East Market States and Outlook (2022-2027) 1.4.7 Africa Market States and Outlook (2022-2027) 1.4.8 Oceania Market States and Outlook (2022-2027) 1.4.9 South America Market States and Outlook (2022-2027) 1.5 Global Alpha 1 Antitrypsin Deficiency Treatment Market Size Analysis from 2022 to 2027 1.5.1 Global Alpha 1 Antitrypsin Deficiency Treatment Market Size Analysis from 2022 to 2027 by Consumption Volume 1.5.2 Global Alpha 1 Antitrypsin Deficiency Treatment Market Size Analysis from 2022 to 2027 by Value 1.5.3 Global Alpha 1 Antitrypsin Deficiency Treatment Price Trends Analysis from 2022 to 2027 1.6 COVID-19 Outbreak: Alpha 1 Antitrypsin Deficiency Treatment Industry Impact Chapter 2 Global Alpha 1 Antitrypsin Deficiency Treatment Competition by Types, Applications, and Top Regions and Countries 2.1 Global Alpha 1 Antitrypsin Deficiency Treatment (Volume and Value) by Type 2.1.1 Global Alpha 1 Antitrypsin Deficiency Treatment Consumption and Market Share by Type (2016-2021) 2.1.2 Global Alpha 1 Antitrypsin Deficiency Treatment Revenue and Market Share by Type (2016-2021) 2.2 Global Alpha 1 Antitrypsin Deficiency Treatment (Volume and Value) by Application 2.2.1 Global Alpha 1 Antitrypsin Deficiency Treatment Consumption and Market Share by Application (2016-2021) 2.2.2 Global Alpha 1 Antitrypsin Deficiency Treatment Revenue and Market Share by Application (2016-2021) 2.3 Global Alpha 1 Antitrypsin Deficiency Treatment (Volume and Value) by Regions 2.3.1 Global Alpha 1 Antitrypsin Deficiency Treatment Consumption and Market Share by Regions (2016-2021) 2.3.2 Global Alpha 1 Antitrypsin Deficiency Treatment Revenue and Market Share by Regions (2016-2021) Chapter 3 Production Market Analysis 3.1 Global Production Market Analysis 3.1.1 2016-2021 Global Capacity, Production, Capacity Utilization Rate, Ex-Factory Price, Revenue, Cost, Gross and Gross Margin Analysis 3.1.2 2016-2021 Major Manufacturers Performance and Market Share 3.2 Regional Production Market Analysis 3.2.1 2016-2021 Regional Market Performance and Market Share 3.2.2 North America Market 3.2.3 East Asia Market 3.2.4 Europe Market 3.2.5 South Asia Market 3.2.6 Southeast Asia Market 3.2.7 Middle East Market 3.2.8 Africa Market 3.2.9 Oceania Market 3.2.10 South America Market 3.2.11 Rest of the World Market Chapter 4 Global Alpha 1 Antitrypsin Deficiency Treatment Sales, Consumption, Export, Import by Regions (2016-2021) 4.1 Global Alpha 1 Antitrypsin Deficiency Treatment Consumption by Regions (2016-2021) 4.2 North America Alpha 1 Antitrypsin Deficiency Treatment Sales, Consumption, Export, Import (2016-2021) 4.3 East Asia Alpha 1 Antitrypsin Deficiency Treatment Sales, Consumption, Export, Import (2016-2021) 4.4 Europe Alpha 1 Antitrypsin Deficiency Treatment Sales, Consumption, Export, Import (2016-2021) 4.5 South Asia Alpha 1 Antitrypsin Deficiency Treatment Sales, Consumption, Export, Import (2016-2021) 4.6 Southeast Asia Alpha 1 Antitrypsin Deficiency Treatment Sales, Consumption, Export, Import (2016-2021) 4.7 Middle East Alpha 1 Antitrypsin Deficiency Treatment Sales, Consumption, Export, Import (2016-2021) 4.8 Africa Alpha 1 Antitrypsin Deficiency Treatment Sales, Consumption, Export, Import (2016-2021) 4.9 Oceania Alpha 1 Antitrypsin Deficiency Treatment Sales, Consumption, Export, Import (2016-2021) 4.10 South America Alpha 1 Antitrypsin Deficiency Treatment Sales, Consumption, Export, Import (2016-2021) Chapter 5 North America Alpha 1 Antitrypsin Deficiency Treatment Market Analysis 5.1 North America Alpha 1 Antitrypsin Deficiency Treatment Consumption and Value Analysis 5.1.1 North America Alpha 1 Antitrypsin Deficiency Treatment Market Under COVID-19 5.2 North America Alpha 1 Antitrypsin Deficiency Treatment Consumption Volume by Types 5.3 North America Alpha 1 Antitrypsin Deficiency Treatment Consumption Structure by Application 5.4 North America Alpha 1 Antitrypsin Deficiency Treatment Consumption by Top Countries 5.4.1 United States Alpha 1 Antitrypsin Deficiency Treatment Consumption Volume from 2016 to 2021 5.4.2 Canada Alpha 1 Antitrypsin Deficiency Treatment Consumption Volume from 2016 to 2021 5.4.3 Mexico Alpha 1 Antitrypsin Deficiency Treatment Consumption Volume from 2016 to 2021 Chapter 6 East Asia Alpha 1 Antitrypsin Deficiency Treatment Market Analysis 6.1 East Asia Alpha 1 Antitrypsin Deficiency Treatment Consumption and Value Analysis 6.1.1 East Asia Alpha 1 Antitrypsin Deficiency Treatment Market Under COVID-19 6.2 East Asia Alpha 1 Antitrypsin Deficiency Treatment Consumption Volume by Types 6.3 East Asia Alpha 1 Antitrypsin Deficiency Treatment Consumption Structure by Application 6.4 East Asia Alpha 1 Antitrypsin Deficiency Treatment Consumption by Top Countries 6.4.1 China Alpha 1 Antitrypsin Deficiency Treatment Consumption Volume from 2016 to 2021 6.4.2 Japan Alpha 1 Antitrypsin Deficiency Treatment Consumption Volume from 2016 to 2021 6.4.3 South Korea Alpha 1 Antitrypsin Deficiency Treatment Consumption Volume from 2016 to 2021 Chapter 7 Europe Alpha 1 Antitrypsin Deficiency Treatment Market Analysis 7.1 Europe Alpha 1 Antitrypsin Deficiency Treatment Consumption and Value Analysis 7.1.1 Europe Alpha 1 Antitrypsin Deficiency Treatment Market Under COVID-19 7.2 Europe Alpha 1 Antitrypsin Deficiency Treatment Consumption Volume by Types 7.3 Europe Alpha 1 Antitrypsin Deficiency Treatment Consumption Structure by Application 7.4 Europe Alpha 1 Antitrypsin Deficiency Treatment Consumption by Top Countries 7.4.1 Germany Alpha 1 Antitrypsin Deficiency Treatment Consumption Volume from 2016 to 2021 7.4.2 UK Alpha 1 Antitrypsin Deficiency Treatment Consumption Volume from 2016 to 2021 7.4.3 France Alpha 1 Antitrypsin Deficiency Treatment Consumption Volume from 2016 to 2021 7.4.4 Italy Alpha 1 Antitrypsin Deficiency Treatment Consumption Volume from 2016 to 2021 7.4.5 Russia Alpha 1 Antitrypsin Deficiency Treatment Consumption Volume from 2016 to 2021 7.4.6 Spain Alpha 1 Antitrypsin Deficiency Treatment Consumption Volume from 2016 to 2021 7.4.7 Netherlands Alpha 1 Antitrypsin Deficiency Treatment Consumption Volume from 2016 to 2021 7.4.8 Switzerland Alpha 1 Antitrypsin Deficiency Treatment Consumption Volume from 2016 to 2021 7.4.9 Poland Alpha 1 Antitrypsin Deficiency Treatment Consumption Volume from 2016 to 2021 Chapter 8 South Asia Alpha 1 Antitrypsin Deficiency Treatment Market Analysis 8.1 South Asia Alpha 1 Antitrypsin Deficiency Treatment Consumption and Value Analysis 8.1.1 South Asia Alpha 1 Antitrypsin Deficiency Treatment Market Under COVID-19 8.2 South Asia Alpha 1 Antitrypsin Deficiency Treatment Consumption Volume by Types 8.3 South Asia Alpha 1 Antitrypsin Deficiency Treatment Consumption Structure by Application 8.4 South Asia Alpha 1 Antitrypsin Deficiency Treatment Consumption by Top Countries 8.4.1 India Alpha 1 Antitrypsin Deficiency Treatment Consumption Volume from 2016 to 2021 8.4.2 Pakistan Alpha 1 Antitrypsin Deficiency Treatment Consumption Volume from 2016 to 2021 8.4.3 Bangladesh Alpha 1 Antitrypsin Deficiency Treatment Consumption Volume from 2016 to 2021 Chapter 9 Southeast Asia Alpha 1 Antitrypsin Deficiency Treatment Market Analysis 9.1 Southeast Asia Alpha 1 Antitrypsin Deficiency Treatment Consumption and Value Analysis 9.1.1 Southeast Asia Alpha 1 Antitrypsin Deficiency Treatment Market Under COVID-19 9.2 Southeast Asia Alpha 1 Antitrypsin Deficiency Treatment Consumption Volume by Types 9.3 Southeast Asia Alpha 1 Antitrypsin Deficiency Treatment Consumption Structure by Application 9.4 Southeast Asia Alpha 1 Antitrypsin Deficiency Treatment Consumption by Top Countries 9.4.1 Indonesia Alpha 1 Antitrypsin Deficiency Treatment Consumption Volume from 2016 to 2021 9.4.2 Thailand Alpha 1 Antitrypsin Deficiency Treatment Consumption Volume from 2016 to 2021 9.4.3 Singapore Alpha 1 Antitrypsin Deficiency Treatment Consumption Volume from 2016 to 2021 9.4.4 Malaysia Alpha 1 Antitrypsin Deficiency Treatment Consumption Volume from 2016 to 2021 9.4.5 Philippines Alpha 1 Antitrypsin Deficiency Treatment Consumption Volume from 2016 to 2021 9.4.6 Vietnam Alpha 1 Antitrypsin Deficiency Treatment Consumption Volume from 2016 to 2021 9.4.7 Myanmar Alpha 1 Antitrypsin Deficiency Treatment Consumption Volume from 2016 to 2021 Chapter 10 Middle East Alpha 1 Antitrypsin Deficiency Treatment Market Analysis 10.1 Middle East Alpha 1 Antitrypsin Deficiency Treatment Consumption and Value Analysis 10.1.1 Middle East Alpha 1 Antitrypsin Deficiency Treatment Market Under COVID-19 10.2 Middle East Alpha 1 Antitrypsin Deficiency Treatment Consumption Volume by Types 10.3 Middle East Alpha 1 Antitrypsin Deficiency Treatment Consumption Structure by Application 10.4 Middle East Alpha 1 Antitrypsin Deficiency Treatment Consumption by Top Countries 10.4.1 Turkey Alpha 1 Antitrypsin Deficiency Treatment Consumption Volume from 2016 to 2021 10.4.2 Saudi Arabia Alpha 1 Antitrypsin Deficiency Treatment Consumption Volume from 2016 to 2021 10.4.3 Iran Alpha 1 Antitrypsin Deficiency Treatment Consumption Volume from 2016 to 2021 10.4.4 United Arab Emirates Alpha 1 Antitrypsin Deficiency Treatment Consumption Volume from 2016 to 2021 10.4.5 Israel Alpha 1 Antitrypsin Deficiency Treatment Consumption Volume from 2016 to 2021 10.4.6 Iraq Alpha 1 Antitrypsin Deficiency Treatment Consumption Volume from 2016 to 2021 10.4.7 Qatar Alpha 1 Antitrypsin Deficiency Treatment Consumption Volume from 2016 to 2021 10.4.8 Kuwait Alpha 1 Antitrypsin Deficiency Treatment Consumption Volume from 2016 to 2021 10.4.9 Oman Alpha 1 Antitrypsin Deficiency Treatment Consumption Volume from 2016 to 2021 Chapter 11 Africa Alpha 1 Antitrypsin Deficiency Treatment Market Analysis 11.1 Africa Alpha 1 Antitrypsin Deficiency Treatment Consumption and Value Analysis 11.1.1 Africa Alpha 1 Antitrypsin Deficiency Treatment Market Under COVID-19 11.2 Africa Alpha 1 Antitrypsin Deficiency Treatment Consumption Volume by Types 11.3 Africa Alpha 1 Antitrypsin Deficiency Treatment Consumption Structure by Application 11.4 Africa Alpha 1 Antitrypsin Deficiency Treatment Consumption by Top Countries 11.4.1 Nigeria Alpha 1 Antitrypsin Deficiency Treatment Consumption Volume from 2016 to 2021 11.4.2 South Africa Alpha 1 Antitrypsin Deficiency Treatment Consumption Volume from 2016 to 2021 11.4.3 Egypt Alpha 1 Antitrypsin Deficiency Treatment Consumption Volume from 2016 to 2021 11.4.4 Algeria Alpha 1 Antitrypsin Deficiency Treatment Consumption Volume from 2016 to 2021 11.4.5 Morocco Alpha 1 Antitrypsin Deficiency Treatment Consumption Volume from 2016 to 2021 Chapter 12 Oceania Alpha 1 Antitrypsin Deficiency Treatment Market Analysis 12.1 Oceania Alpha 1 Antitrypsin Deficiency Treatment Consumption and Value Analysis 12.2 Oceania Alpha 1 Antitrypsin Deficiency Treatment Consumption Volume by Types 12.3 Oceania Alpha 1 Antitrypsin Deficiency Treatment Consumption Structure by Application 12.4 Oceania Alpha 1 Antitrypsin Deficiency Treatment Consumption by Top Countries 12.4.1 Australia Alpha 1 Antitrypsin Deficiency Treatment Consumption Volume from 2016 to 2021 12.4.2 New Zealand Alpha 1 Antitrypsin Deficiency Treatment Consumption Volume from 2016 to 2021 Chapter 13 South America Alpha 1 Antitrypsin Deficiency Treatment Market Analysis 13.1 South America Alpha 1 Antitrypsin Deficiency Treatment Consumption and Value Analysis 13.1.1 South America Alpha 1 Antitrypsin Deficiency Treatment Market Under COVID-19 13.2 South America Alpha 1 Antitrypsin Deficiency Treatment Consumption Volume by Types 13.3 South America Alpha 1 Antitrypsin Deficiency Treatment Consumption Structure by Application 13.4 South America Alpha 1 Antitrypsin Deficiency Treatment Consumption Volume by Major Countries 13.4.1 Brazil Alpha 1 Antitrypsin Deficiency Treatment Consumption Volume from 2016 to 2021 13.4.2 Argentina Alpha 1 Antitrypsin Deficiency Treatment Consumption Volume from 2016 to 2021 13.4.3 Columbia Alpha 1 Antitrypsin Deficiency Treatment Consumption Volume from 2016 to 2021 13.4.4 Chile Alpha 1 Antitrypsin Deficiency Treatment Consumption Volume from 2016 to 2021 13.4.5 Venezuela Alpha 1 Antitrypsin Deficiency Treatment Consumption Volume from 2016 to 2021 13.4.6 Peru Alpha 1 Antitrypsin Deficiency Treatment Consumption Volume from 2016 to 2021 13.4.7 Puerto Rico Alpha 1 Antitrypsin Deficiency Treatment Consumption Volume from 2016 to 2021 13.4.8 Ecuador Alpha 1 Antitrypsin Deficiency Treatment Consumption Volume from 2016 to 2021 Chapter 14 Company Profiles and Key Figures in Alpha 1 Antitrypsin Deficiency Treatment Business 14.1 Pfizer 14.1.1 Pfizer Company Profile 14.1.2 Pfizer Alpha 1 Antitrypsin Deficiency Treatment Product Specification 14.1.3 Pfizer Alpha 1 Antitrypsin Deficiency Treatment Production Capacity, Revenue, Price and Gross Margin (2016-2021) 14.2 Baxter 14.2.1 Baxter Company Profile 14.2.2 Baxter Alpha 1 Antitrypsin Deficiency Treatment Product Specification 14.2.3 Baxter Alpha 1 Antitrypsin Deficiency Treatment Production Capacity, Revenue, Price and Gross Margin (2016-2021) 14.3 AstraZeneca 14.3.1 AstraZeneca Company Profile 14.3.2 AstraZeneca Alpha 1 Antitrypsin Deficiency Treatment Product Specification 14.3.3 AstraZeneca Alpha 1 Antitrypsin Deficiency Treatment Production Capacity, Revenue, Price and Gross Margin (2016-2021) 14.4 Grifols 14.4.1 Grifols Company Profile 14.4.2 Grifols Alpha 1 Antitrypsin Deficiency Treatment Product Specification 14.4.3 Grifols Alpha 1 Antitrypsin Deficiency Treatment Production Capacity, Revenue, Price and Gross Margin (2016-2021) 14.5 Teva Pharmaceutical Industries 14.5.1 Teva Pharmaceutical Industries Company Profile 14.5.2 Teva Pharmaceutical Industries Alpha 1 Antitrypsin Deficiency Treatment Product Specification 14.5.3 Teva Pharmaceutical Industries Alpha 1 Antitrypsin Deficiency Treatment Production Capacity, Revenue, Price and Gross Margin (2016-2021) 14.6 Boehringer Ingelheim 14.6.1 Boehringer Ingelheim Company Profile 14.6.2 Boehringer Ingelheim Alpha 1 Antitrypsin Deficiency Treatment Product Specification 14.6.3 Boehringer Ingelheim Alpha 1 Antitrypsin Deficiency Treatment Production Capacity, Revenue, Price and Gross Margin (2016-2021) 14.7 Kamada Ltd 14.7.1 Kamada Ltd Company Profile 14.7.2 Kamada Ltd Alpha 1 Antitrypsin Deficiency Treatment Product Specification 14.7.3 Kamada Ltd Alpha 1 Antitrypsin Deficiency Treatment Production Capacity, Revenue, Price and Gross Margin (2016-2021) 14.8 GlaxoSmithKline 14.8.1 GlaxoSmithKline Company Profile 14.8.2 GlaxoSmithKline Alpha 1 Antitrypsin Deficiency Treatment Product Specification 14.8.3 GlaxoSmithKline Alpha 1 Antitrypsin Deficiency Treatment Production Capacity, Revenue, Price and Gross Margin (2016-2021) 14.9 CSL Behring 14.9.1 CSL Behring Company Profile 14.9.2 CSL Behring Alpha 1 Antitrypsin Deficiency Treatment Product Specification 14.9.3 CSL Behring Alpha 1 Antitrypsin Deficiency Treatment Production Capacity, Revenue, Price and Gross Margin (2016-2021) 14.10 Shire 14.10.1 Shire Company Profile 14.10.2 Shire Alpha 1 Antitrypsin Deficiency Treatment Product Specification 14.10.3 Shire Alpha 1 Antitrypsin Deficiency Treatment Production Capacity, Revenue, Price and Gross Margin (2016-2021) 14.11 LFB Biomedicaments 14.11.1 LFB Biomedicaments Company Profile 14.11.2 LFB Biomedicaments Alpha 1 Antitrypsin Deficiency Treatment Product Specification 14.11.3 LFB Biomedicaments Alpha 1 Antitrypsin Deficiency Treatment Production Capacity, Revenue, Price and Gross Margin (2016-2021) 14.12 Abeona Therapeutics 14.12.1 Abeona Therapeutics Company Profile 14.12.2 Abeona Therapeutics Alpha 1 Antitrypsin Deficiency Treatment Product Specification 14.12.3 Abeona Therapeutics Alpha 1 Antitrypsin Deficiency Treatment Production Capacity, Revenue, Price and Gross Margin (2016-2021) 14.13 Biogen 14.13.1 Biogen Company Profile 14.13.2 Biogen Alpha 1 Antitrypsin Deficiency Treatment Product Specification 14.13.3 Biogen Alpha 1 Antitrypsin Deficiency Treatment Production Capacity, Revenue, Price and Gross Margin (2016-2021) 14.14 Applied Genetic Technologies 14.14.1 Applied Genetic Technologies Company Profile 14.14.2 Applied Genetic Technologies Alpha 1 Antitrypsin Deficiency Treatment Product Specification 14.14.3 Applied Genetic Technologies Alpha 1 Antitrypsin Deficiency Treatment Production Capacity, Revenue, Price and Gross Margin (2016-2021) 14.15 Baxalta 14.15.1 Baxalta Company Profile 14.15.2 Baxalta Alpha 1 Antitrypsin Deficiency Treatment Product Specification 14.15.3 Baxalta Alpha 1 Antitrypsin Deficiency Treatment Production Capacity, Revenue, Price and Gross Margin (2016-2021) 14.16 Arrowhead Research Corporation 14.16.1 Arrowhead Research Corporation Company Profile 14.16.2 Arrowhead Research Corporation Alpha 1 Antitrypsin Deficiency Treatment Product Specification 14.16.3 Arrowhead Research Corporation Alpha 1 Antitrypsin Deficiency Treatment Production Capacity, Revenue, Price and Gross Margin (2016-2021) 14.17 ProBioGen 14.17.1 ProBioGen Company Profile 14.17.2 ProBioGen Alpha 1 Antitrypsin Deficiency Treatment Product Specification 14.17.3 ProBioGen Alpha 1 Antitrypsin Deficiency Treatment Production Capacity, Revenue, Price and Gross Margin (2016-2021) 14.18 Chiesi Pharmaceuticals 14.18.1 Chiesi Pharmaceuticals Company Profile 14.18.2 Chiesi Pharmaceuticals Alpha 1 Antitrypsin Deficiency Treatment Product Specification 14.18.3 Chiesi Pharmaceuticals Alpha 1 Antitrypsin Deficiency Treatment Production Capacity, Revenue, Price and Gross Margin (2016-2021) 14.19 Curaxys 14.19.1 Curaxys Company Profile 14.19.2 Curaxys Alpha 1 Antitrypsin Deficiency Treatment Product Specification 14.19.3 Curaxys Alpha 1 Antitrypsin Deficiency Treatment Production Capacity, Revenue, Price and Gross Margin (2016-2021) 14.20 ProMetic Life Sciences 14.20.1 ProMetic Life Sciences Company Profile 14.20.2 ProMetic Life Sciences Alpha 1 Antitrypsin Deficiency Treatment Product Specification 14.20.3 ProMetic Life Sciences Alpha 1 Antitrypsin Deficiency Treatment Production Capacity, Revenue, Price and Gross Margin (2016-2021) Chapter 15 Global Alpha 1 Antitrypsin Deficiency Treatment Market Forecast (2022-2027) 15.1 Global Alpha 1 Antitrypsin Deficiency Treatment Consumption Volume, Revenue and Price Forecast (2022-2027) 15.1.1 Global Alpha 1 Antitrypsin Deficiency Treatment Consumption Volume and Growth Rate Forecast (2022-2027) 15.1.2 Global Alpha 1 Antitrypsin Deficiency Treatment Value and Growth Rate Forecast (2022-2027) 15.2 Global Alpha 1 Antitrypsin Deficiency Treatment Consumption Volume, Value and Growth Rate Forecast by Region (2022-2027) 15.2.1 Global Alpha 1 Antitrypsin Deficiency Treatment Consumption Volume and Growth Rate Forecast by Regions (2022-2027) 15.2.2 Global Alpha 1 Antitrypsin Deficiency Treatment Value and Growth Rate Forecast by Regions (2022-2027) 15.2.3 North America Alpha 1 Antitrypsin Deficiency Treatment Consumption Volume, Revenue and Growth Rate Forecast (2022-2027) 15.2.4 East Asia Alpha 1 Antitrypsin Deficiency Treatment Consumption Volume, Revenue and Growth Rate Forecast (2022-2027) 15.2.5 Europe Alpha 1 Antitrypsin Deficiency Treatment Consumption Volume, Revenue and Growth Rate Forecast (2022-2027) 15.2.6 South Asia Alpha 1 Antitrypsin Deficiency Treatment Consumption Volume, Revenue and Growth Rate Forecast (2022-2027) 15.2.7 Southeast Asia Alpha 1 Antitrypsin Deficiency Treatment Consumption Volume, Revenue and Growth Rate Forecast (2022-2027) 15.2.8 Middle East Alpha 1 Antitrypsin Deficiency Treatment Consumption Volume, Revenue and Growth Rate Forecast (2022-2027) 15.2.9 Africa Alpha 1 Antitrypsin Deficiency Treatment Consumption Volume, Revenue and Growth Rate Forecast (2022-2027) 15.2.10 Oceania Alpha 1 Antitrypsin Deficiency Treatment Consumption Volume, Revenue and Growth Rate Forecast (2022-2027) 15.2.11 South America Alpha 1 Antitrypsin Deficiency Treatment Consumption Volume, Revenue and Growth Rate Forecast (2022-2027) 15.3 Global Alpha 1 Antitrypsin Deficiency Treatment Consumption Volume, Revenue and Price Forecast by Type (2022-2027) 15.3.1 Global Alpha 1 Antitrypsin Deficiency Treatment Consumption Forecast by Type (2022-2027) 15.3.2 Global Alpha 1 Antitrypsin Deficiency Treatment Revenue Forecast by Type (2022-2027) 15.3.3 Global Alpha 1 Antitrypsin Deficiency Treatment Price Forecast by Type (2022-2027) 15.4 Global Alpha 1 Antitrypsin Deficiency Treatment Consumption Volume Forecast by Application (2022-2027) 15.5 Alpha 1 Antitrypsin Deficiency Treatment Market Forecast Under COVID-19 Chapter 16 Conclusions Research Methodology
Related reports
Pharmaceutical Grade Sodium Chloride Market
$2850-$4575
Adenosine Triphosphate ATP Test Kit Market
$3300-$7000
Alpha 1 Antitrypsin Deficiency Treatment Market
$3300-$7000